Our researchers at the University of Cambridge have found that patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test.
Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.
3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.
A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).
More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.
Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.
Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.
The Medicines and Healthcare products Regulatory Agency has approved the first-of-its-kind drug sotorasib for some people with non small cell lung cancer.
A potentially life-extending treatment for some people with non small cell lung cancer (NSCLC) will now be available on the NHS in England.